Editas Medicine, Inc.
NASDAQ:EDIT · NASDAQ Global Select
+$0.07 today
Vol 3.28M · Avg 2.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-586.6%
avg -97.5%
ROIC
-65.6%
avg -42.2%
ROA
-85.8%
avg -41.2%
Analysis
ROIC is currently the strongest return metric at -65.6% versus its period average of -42.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gilmore O'Neill | President, Chief Executive Officer & Director | $1.07M | — | 62 | $248,313.00 | 0.25% |
Linda C. Burkly | Executive Vice President & Chief Scientific Officer | $734,972.00 | — | 69 | $67,297.00 | 0.07% |
Amy Parison | Senior Vice President & Chief Financial Officer | $555,520.00 | — | 40 | $14,970.00 | 0.02% |
Brieana Buckley | Senior Vice President of Development and Program Leadership | — | — | — | — | — |
Feng Zhang | Co-Founder & Scientific Advisory Board Member | — | — | — | $480,769.00 | 0.49% |
George McDonald Church | Co-Founder & Scientific Advisory Board Member | — | — | 72 | $480,769.00 | 0.49% |
Damien Grierson | Senior Vice President, General Counsel & Corporate Secretary | — | — | — | — | — |
Frank Panaccio | Senior Vice President & Chief Business Officer | — | — | — | $60,000.00 | 0.06% |
Gregory Whitehead | Executive Vice President and Chief Technical & Quality Officer | — | — | — | — | — |
Cristi Barnett | Senior Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Tom Love | Vice President of People | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$104,785.05
Net Sentiment
$104,785.05
Net selling
Most Active
Parison Amy
5 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $104,785.05 over the last 12 months. That adds up to net selling of $104,785.05. Parison Amy was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +1.8% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +1.8% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.31B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$488.98M
Cabaletta Bio, Inc.
NASDAQ:CABA
$469.19M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$348.58M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$348.49M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$347.32M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.05M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.56M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$195.44M
Immutep Limited
NASDAQ:IMMP
$55.44M
Who manages EDIT?
Editas Medicine, Inc. (EDIT) lists 11 active executives. The top listed executive is Brieana Buckley, Senior Vice President of Development and Program Leadership.
Are EDIT insiders buying or selling?
Recent insider activity shows net buying of $56.64M.
Explore More
Continue the stock analysis
Jump to another research area for this company.